 GROUP A: Patients receive SVN53-67M57-KLH peptide vaccine in incomplete Freunds adjuvant subcutaneously SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy orally PO once daily QD in the absence of disease progression or unacceptable toxicity. 